CeNeS Pharmaceuticals PLC Strengthens The Patent Portfolio For Its Lead Clinical Programme M6G (Morphine-6-Glucuronide)

CeNeS Pharmaceuticals plc (AIM: CEN) (‘CeNeS’ or ‘the Company’) today announced that it has been granted a new composition of matter patent on a novel salt form of M6G by the European Patent Office. The invention relates to a salt of M6G with improved stability and to the therapeutic use of the salt. The granted patent is registered in 21 European countries. The new patent expires in 2022 and has the potential to extend and strengthen the protection provided by the existing process patents.